J. Jimeno

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

L. Zelek, M. Spielmann, E. Brain, 2006, British Journal of Cancer.

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

F. Grosso, P. Casali, P. Dileo, 2006, European journal of cancer.

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

E. Raymond, F. Goldwasser, P. Cottu, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.